16:04:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-06 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2023-11-22 Årsstämma 2024
2023-10-13 Bonusutdelning CHR 7.72
2023-10-12 Bokslutskommuniké 2023
2023-07-06 Kvartalsrapport 2023-Q3
2023-04-13 Kvartalsrapport 2023-Q2
2023-03-30 Extra Bolagsstämma 2023
2023-01-12 Kvartalsrapport 2023-Q1
2022-11-24 Ordinarie utdelning CHR 7.04 DKK
2022-11-23 Årsstämma 2023
2022-10-12 Bokslutskommuniké 2022
2022-07-07 Kvartalsrapport 2022-Q3
2022-04-06 Kvartalsrapport 2022-Q2
2022-01-13 Kvartalsrapport 2022-Q1
2021-11-25 Ordinarie utdelning CHR 6.54 DKK
2021-11-24 Årsstämma 2022
2021-10-14 Bokslutskommuniké 2021
2021-07-08 Kvartalsrapport 2021-Q3
2021-05-18 Bonusutdelning CHR 6.54
2021-04-15 Kvartalsrapport 2021-Q2
2021-01-14 Kvartalsrapport 2021-Q1
2020-11-26 Ordinarie utdelning CHR 0.00 DKK
2020-11-25 Årsstämma 2021
2020-10-08 Bokslutskommuniké 2020
2020-07-02 Kvartalsrapport 2020-Q3
2020-04-16 Kvartalsrapport 2020-Q2
2020-01-15 Kvartalsrapport 2020-Q1
2019-11-28 Ordinarie utdelning CHR 7.07 DKK
2019-11-27 Årsstämma 2020
2019-10-10 Bokslutskommuniké 2019
2019-07-03 Kvartalsrapport 2019-Q3
2019-04-03 Kvartalsrapport 2019-Q2
2019-01-17 Kvartalsrapport 2019-Q1
2018-11-30 Ordinarie utdelning CHR 6.47 DKK
2018-11-29 Årsstämma 2019
2018-10-15 Bokslutskommuniké 2018
2018-06-29 Bonusutdelning CHR 5.94
2018-06-28 Kvartalsrapport 2018-Q3
2018-04-11 Kvartalsrapport 2018-Q2
2018-01-12 Kvartalsrapport 2018-Q1
2017-11-29 Ordinarie utdelning CHR 6.33 DKK
2017-11-29 Årsstämma 2018
2017-11-28 Årsstämma 2018
2017-10-25 Bokslutskommuniké 2017
2017-07-11 Bonusutdelning CHR 5.64
2017-07-05 Kvartalsrapport 2017-Q3
2017-04-06 Kvartalsrapport 2017-Q2
2017-01-11 Kvartalsrapport 2017-Q1
2016-11-30 Ordinarie utdelning CHR 5.23 DKK
2016-11-29 Årsstämma 2017
2016-10-26 Bokslutskommuniké 2016
2016-07-05 Kvartalsrapport 2016-Q3
2016-04-07 Kvartalsrapport 2016-Q2
2016-01-14 Kvartalsrapport 2016-Q1
2015-11-27 Ordinarie utdelning CHR 4.70 DKK
2015-11-26 Årsstämma 2016
2015-10-21 Bokslutskommuniké 2015
2015-07-07 Bonusutdelning CHR 6.57
2015-07-01 Kvartalsrapport 2015-Q3
2015-04-09 Kvartalsrapport 2015-Q2
2015-01-21 Kvartalsrapport 2015-Q1
2014-11-28 Ordinarie utdelning CHR 3.77 DKK
2014-11-27 Årsstämma 2015
2014-10-22 Bokslutskommuniké 2014
2014-07-02 Kvartalsrapport 2014-Q3
2014-04-09 Kvartalsrapport 2014-Q2
2014-01-15 Kvartalsrapport 2014-Q1
2013-11-27 Bonusutdelning CHR 3.13
2013-11-27 Ordinarie utdelning CHR 3.13 DKK
2013-11-26 Årsstämma 2014
2013-10-23 Bokslutskommuniké 2013
2013-07-03 Kvartalsrapport 2013-Q3
2013-04-11 Kvartalsrapport 2013-Q2
2013-01-16 Kvartalsrapport 2013-Q1
2012-11-28 Ordinarie utdelning CHR 2.90 DKK
2012-11-27 Årsstämma 2013
2012-07-04 Kvartalsrapport 2012-Q3
2012-04-19 Kvartalsrapport 2012-Q2
2012-01-11 Kvartalsrapport 2012-Q1
2011-11-30 Ordinarie utdelning CHR 3.57 DKK
2011-11-29 Årsstämma 2012
2011-07-06 Kvartalsrapport 2011-Q3
2011-04-06 Kvartalsrapport 2011-Q2
2011-01-12 Kvartalsrapport 2011-Q1
2010-12-01 Ordinarie utdelning CHR 0.64 DKK


ListaLarge Cap Copenhagen
Christian Hansen Holding är en global livsmedelskoncern. Bolagets affärsinriktning återfinns inom utveckling av enzymer och naturliga färger som används som tillsatser inom livsmedelsindustrin. En stor del inom verksamheten innefattar forskning och utveckling av goda bakterier som tillsätts i probiotikaprodukter. Bolaget grundades ursprungligen 1874 och har sitt huvudkontor i Hørsholm.
2022-04-06 08:00:00

Company announcement no. 03/2022

April 6, 2022

Strong Q2 growth in a challenging environment

Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Growth in Health & Nutrition further accelerated, supported by Human Health, while Food Cultures & Enzymes showed solid growth, mainly driven by its core segments and developed markets. In the second quarter, the EBIT margin b.s.i. increased to 27.7% thanks to strong volume growth. The performance in the first half of the year provides a robust foundation for delivering on our ambitions for the full year. However, overall market volatility has increased due to the accelerating inflationary pressure and the Russian invasion of Ukraine. We are responding to the higher cost inflation with proactive pricing measures and are adjusting our outlook by upgrading our organic revenue growth target, while also lowering expectations for the near-term EBIT margin b.s.i. The net effect is expected to be largely neutral on EBIT b.s.i., consistent with our prior guidance, and we maintain our expectations for free cash flow b.s.i.”

Q2 2021/22 highlights

  • Revenue amounted to EUR 304 million, up 17% from EUR 260 million in Q2 2020/21. Year-to-date revenue amounted to 572 million, up 14% from last year.
  • Organic growth was 14% in Q2 2021/22 mainly driven by volume growth. The Lighthouses (Bioprotection, Fermented Plant Bases, Plant Health and HMO) delivered 12% organic growth combined, while the remaining core businesses delivered 14% organic growth. Year-to-date organic growth was 12%.
    • Food Cultures & Enzymes organic growth was 7% mainly driven by volume. Year-to-date organic growth was 7%.
    • Health & Nutrition organic growth was 26% driven by volume. Year-to-date organic growth was 20%.
  • EBIT before special items (b.s.i.) amounted to EUR 84 million, up 20% from EUR 70 million in Q2 2020/21. The increase was driven by the strong sales performance in Health and Nutrition, while EBIT b.s.i. in Food Cultures & Enzymes was on par with the Q2 2020/21 level due to a negative impact from higher input costs. Year-to-date EBIT b.s.i. amounted to EUR 150 million, up 14% from last year.
  • The EBIT margin b.s.i. was 27.7%, up from 27.0% in Q2 2020/21. Production efficiencies, scalability effects from the strong sales performance, and a positive impact from currencies were partly offset by higher input costs and a general ramp-up of activities. Year-to-date EBIT margin b.s.i. was 26.2%, compared to 26.1% last year.
  • Free cash flow before acquisitions and special items (b.a.s.i.) amounted to EUR 31 million, down EUR 11 million from Q2 2020/21, as improved operating profit was offset by increased investing activities and a change in working capital. Year-to-date free cash flow b.a.s.i. amounted to EUR 86 million, up from EUR 35 million last year. The increase was due to both improved cash flow from operating activities and reduced operational investing activities.
  • The Russian invasion of Ukraine and its geopolitical consequences have impacted Chr. Hansen as a global supplier to the food and health industries. We will continue to support our Ukrainian employees and customers and, for now, will fulfill our supply obligations to provide only ingredients for basic food and human health products to Russia servicing the basic needs of civilians in full respect of global sanctions. The situation will have a negative impact on the outlook for the year causing both a lower topline and a reduced EBIT. Profit from continued operations in Chr. Hansen LLC, Russia during the conflict will be donated to humanitarian aid in support of Ukraine.
  • Implementation of price adjustments to reflect the inflationary pressure is progressing, however, as expected, with modest impact in Q2. Given the accelerated inflationary pressure on raw material, energy and logistics costs, in part driven by the Russian invasion of Ukraine, further price increases will be introduced in the second half. This will come with a certain delay impacting the outlook for the EBIT margin before special items for 2021/22 negatively.


Due to the current geopolitical situation and the accelerating inflationary environment we adjust the 2021/22 outlook for organic revenue growth and EBIT margin b.s.i., while maintaining the outlook for the free cash flow b.s.i. relative to the guidance provided on January 13, 2022.

  • Organic growth is expected in the range of 7-11% (previously 5-8%).
  • EBIT margin before special items is expected to be 26-27% (previously 27-28%).
  • Free cash flow before special items is expected to be around EURm 140-170 (unchanged).


See attachment for full Q2 2021/22 interim report.

For further information, please contact:

Anders Mohr Christensen
VP Group Strategy & Investor Relations
Mobile: +45 25 15 23 64

Annika Stern
Senior Investor Relations Manager
Mobile: +45 23 99 23 82

Sanne Seyer-Hansen
Head of Corporate Comunications
Mobile: +45 60 38 62 07

About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable biotech company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.